Results 31 to 40 of about 169,915 (161)
, 2011 THE BENEFIT OF SOY BEAN- CHOCOLATE BEVERAGE ON BONE RESORPTION IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS\ud Nur Ainun Rani1, Nurpudji A. Taslim,1,2 Haerani Rasyid1,2, Burhanuddin Bahar3\ud Department of Clinical Nutrition Faculty of Medicine 1 ...
Rasyid, Haerani +3 more
core
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
, 2009 Roberto Cesareo1, Clemente Napolitano1, Mario Iozzino21Department of Internal Medicine, 2Department of Radiology, S.M. Goretti Hospital, Latina, ItalyAbstract: Osteoporosis is a progressive and debilitating disease characterized by a massive bone loss ...
Roberto Cesareo +2 more
core
, 2017 Introduction. Postmenopausal women one of the most critical periods in which modern woman spends a third of her life, and therefore the study of this problem is of particular interest.
Butovа T.
core +1 more source
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
, 2011 Hisaya Kawate, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Bazedoxifene, a novel selective estrogen receptor modulator, has been developed to have ...
Ryoichi Takayanagi +3 more
core +1 more source
Postmenopausal women – comorbid patients
, 2020 Relevance. As the prevention and treatment of diseases improves, the average life expectancy of the population increases. For many of our contemporaries, a third of their lives are postmenopausal. Menopause-related health problems are increasingly common
Tatyana Yu. Pestrikova +3 more
core +1 more source
Prevalence of Thyroid Dysfunction Among Postmenopausal Women in Baghdad Medical City [PDF]
Background: One of the most frequent endocrine abnormalities and changes in females, especially during the postmenopausal period, is thyroid dysfunction.
Hayder AL-MOMEN +4 more
core +1 more source
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
, 2009 E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USAAbstract: Lasofoxifene is a selective estrogen receptor modulator (estrogen agonist/antagonist) that has completed phase III trials to evaluate ...
E Michael Lewiecki
core
Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy
, 2014 Mary Jane Minkin,1 Ricardo Maamari,2 Suzanne Reiter3 1Department of Gynecology and Reproductive Medicine, Yale University School of Medicine, New Haven, CT, USA; 2Novo Nordisk Inc., Plainsboro, NJ, USA; 3Mid-County Health Center, Largo, FL, USA Abstract:
Minkin MJ, Maamari R, Reiter S
core
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
, 2008 E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of ...
E Michael Lewiecki
core
, 2008 Jun Iwamoto1, Yoshihiro Sato2, Tsuyoshi Takeda1, Hideo Matsumoto21Department of Sports Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Neurology, Mitate Hospital, Fukuoka, JapanAbstract: Osteoporosis most commonly affects ...
Jun Iwamoto +3 more
core